Saxenda

Also known as: Liraglutide Injection (Saxenda) · Daily Liraglutide for Weight Management · High-Dose Liraglutide

Definition

Saxenda is a brand name for once-daily subcutaneous injectable liraglutide approved for chronic weight management. It is indicated as an adjunct to a reduced-calorie diet and increased physical activity for chronic weight management in adults with a body mass index (BMI) of 30 kg/m² or greater (obesity), or 27 kg/m² or greater (overweight) in the presence of at least one weight-related comorbidity (e.g., dyslipidemia, hypertension, or type 2 diabetes mellitus). It is also approved for weight management in pediatric patients aged 12 to 17 years with a body weight above 60 kg and obesity. Developed and manufactured by Novo Nordisk, Saxenda contains the same active ingredient as Victoza but is administered at a higher target maintenance dose of 3.0 mg daily. (FDA, NovoNordisk)

Saxenda acts as a glucagon-like peptide-1 (GLP-1) receptor agonist, sharing 97% sequence homology with endogenous human GLP-1. By binding to and activating GLP-1 receptors in the brain, particularly in the hypothalamus, it helps regulate appetite. The drug increases signals that communicate fullness (satiety) and decreases signals that drive hunger. It also slows gastric emptying, delaying the passage of food through the digestive tract, which prolongs the feeling of fullness and supports adherence to a calorie-restricted diet. (NCBI, EMA)

Identities

Source Type	Identity
Wikipedia	Liraglutide
Wikidata	Q110292558
DBpedia	Liraglutide
ProductOntology	N/A
Wiktionary	Saxenda
Library of Congress Subject Headings (LCSH)	N/A
MeSH	Saxenda
NCBI Taxonomy	N/A
AGROVOC	N/A
Google Scholar	Saxenda liraglutide obesity Philippines
ConceptNet	Saxenda
OpenCyc	N/A

Also Known As

Liraglutide Injection (Saxenda)
Daily Liraglutide for Weight Management
High-Dose Liraglutide

Geography and Climate

In the tropical climate of the Philippines, characterized by high humidity and temperatures that frequently exceed 30°C, proper storage is critical to maintain Saxenda’s stability. As a peptide biologic, liraglutide is sensitive to heat, and exposure to high temperatures or direct sunlight can cause it to break down, reducing its effectiveness.

Before its first use, Saxenda pens must be stored in a refrigerator at temperatures between 2°C and 8°C. Once in use, the pen can be kept at room temperature (not exceeding 30°C) or in the refrigerator for up to 30 days. Patients in the Philippines are advised to use insulated travel bags with cold packs when transporting the drug from pharmacies. In areas with frequent power outages, especially during the typhoon season, patients must plan for alternative cold storage options, such as dedicated coolers, to protect their medication supply.

Demographics

The clinical use of Saxenda in the Philippines is driven by the country’s rising rates of obesity and overweight. Data from the Food and Nutrition Research Institute (FNRI) show a steady increase in weight-related issues among Filipino adults, particularly in urban areas. Saxenda is prescribed to patients who meet the clinical BMI criteria and require medical support to achieve weight loss.

In urban areas like Metro Manila, Metro Cebu, and Metro Davao, Saxenda is commonly prescribed to adults with sedentary lifestyles, including professionals in the Business Process Outsourcing (BPO) sector. The irregular working hours, high stress, and limited availability of healthy food options during night shifts contribute to metabolic issues and weight gain. Additionally, women with weight-management difficulties related to PCOS are a significant patient subgroup, as weight reduction can help manage symptoms and improve metabolic health.

Economy and Industry

Saxenda is distributed in the Philippines through major retail pharmacy chains, including Mercury Drug and Watsons. It is classified as a premium medication, and patients pay for it out-of-pocket. National health insurance schemes like PhilHealth do not cover medications prescribed for weight management, making the cost of long-term therapy a significant out-of-pocket healthcare expense.

The introduction of Saxenda has contributed to the expansion of the private medical weight loss and aesthetic wellness sectors in the Philippines. Wellness clinics and private medical practices in major cities offer structured weight loss programs that combine Saxenda therapy with medical monitoring, laboratory tests, and dietary counseling. The monthly cost of treatment packages has made this therapy accessible primarily to middle- and upper-income groups.

Transportation and Infrastructure

The supply chain for Saxenda in the Philippines relies on temperature-controlled logistics. The medication is imported into hubs in Manila and stored in climate-controlled warehouses. Distribution to pharmacies across the country requires refrigerated trucks and careful temperature logging to prevent exposure to extreme heat during transport across the islands.

In major cities, the retail pharmacy infrastructure is supported by backup generators to ensure cold storage during power outages. However, rural areas and smaller islands face logistics challenges, including transport delays and limited cold storage facilities. These infrastructure limitations can affect product availability, requiring patients in remote areas to travel to larger urban centers to fill their prescriptions.

Culture and Tourism

The popularity of Saxenda on social media platforms like TikTok, Facebook, and Instagram has influenced public discussions on weight management in the Philippines. Users sharing their daily injection routines and weight-loss progress have led to high public interest. This viral attention has raised awareness about obesity as a clinical condition, though it has also increased interest in using the drug for cosmetic weight loss.

The medical tourism sector has also responded to this interest. Private clinics in Metro Manila offer weight management programs to international patients and returning overseas Filipinos. These clinics provide medical check-ups, lifestyle counseling, and Saxenda therapy. The availability of English-speaking healthcare professionals and lower consultation fees compared to Western nations make the Philippines an option for patients seeking comprehensive weight management care.

Government and Administration

The Philippine Food and Drug Administration (FDA) is the regulatory authority responsible for approving and monitoring Saxenda. It is classified as a prescription-only (Rx) medication. Pharmacies are required to verify a doctor’s prescription before dispensing the drug. The FDA monitors the market to prevent the distribution of unregistered or counterfeit Saxenda pens, which present risks due to uncertain sterility and content.

The Department of Health (DOH) supports clinical guidelines that emphasize using Saxenda under medical supervision and in combination with lifestyle changes. Regulatory notices remind the public that Saxenda is not indicated for cosmetic weight loss in individuals who do not meet the clinical criteria. The Bureau of Customs works with the FDA to inspect imports and verify that temperature-tracking protocols are followed during transit.

Education and Healthcare

Educational programs for healthcare providers in the Philippines, led by the Philippine Association for the Study of Overweight and Obesity (PASOO) and the Philippine Society of Endocrinology, Diabetes and Metabolism (PSEDM), focus on the clinical data for Saxenda. Studies like the SCALE clinical trial program, which demonstrated significant weight loss and glycemic improvements in patients treated with daily 3.0 mg liraglutide, are key elements of local medical education.

Patient education is an important part of prescribing Saxenda. Nurses and clinical educators train patients on the proper daily subcutaneous injection technique. The training covers selecting an injection site (abdomen, thigh, or upper arm), rotating sites daily, and using the pre-filled pen. Patients also receive counseling on potential digestive side effects, such as nausea or diarrhea, and are advised to maintain hydration and follow a balanced diet.

Examples and Analogies

An analogy for Saxenda is a daily adjustable volume limiter on an audio sound system. When the volume (representing appetite and food cravings) is set too high, it can lead to constant disruption and high energy consumption. The volume limiter helps lower the sound to a manageable, balanced level based on system feedback (releasing GLP-1 hormones), requiring a daily calibration (once-daily injection) to maintain a steady and comfortable level of activity. This helps reduce strain on the system’s components (cardiovascular protection).

A clinical example of Saxenda’s action is the slow digestion of food. In individuals with obesity, rapid digestion can lead to quick returns of hunger after eating. By delaying gastric emptying, Saxenda keeps food in the stomach for a longer period. This action prolongs the physical sensation of fullness, helping patients maintain smaller portions and adhere to their dietary plans.

Usage Scenarios

1. Chronic Weight Management and Metabolic Health

A 42-year-old male in Quezon City with a BMI of 33 kg/m² and dyslipidemia has not achieved sustainable weight loss through diet and exercise alone. His doctor prescribes once-daily injections of Saxenda, starting at 0.6 mg and titrating up weekly to the maintenance dose of 3.0 mg. Over six months, the patient loses 10% of his starting body weight, and his lipid profile shows improvement.

2. Weight Management Support for Adolescents

A 15-year-old female in Cebu City with clinical obesity and a body weight of 75 kg is evaluated by a pediatric endocrinologist. Following lifestyle modifications, the doctor prescribes Saxenda daily. The treatment, combined with family-supported dietary changes, helps reduce her appetite, leading to consistent weight management and improved energy levels.

Strategies

Start Saxenda at a low dose (0.6 mg once daily) and increase it weekly by 0.6 mg to reach the 3.0 mg maintenance dose, helping the digestive system adjust and minimizing nausea.
Administer the injection at approximately the same time every day, and rotate the injection site among the abdomen, thigh, and upper arm.
If a dose is missed, administer it if remembered within 12 hours of the usual time; otherwise, skip the missed dose and resume the next day. If missed for more than 3 days, restart at 0.6 mg and retitrate.
Consume smaller meals and eat slowly to avoid feelings of excessive fullness or nausea caused by the delayed emptying of the stomach.

Security and Safety Measures

Boxed Warning: Do not prescribe Saxenda to patients with a personal or family history of medullary thyroid carcinoma (MTC) or Multiple Endocrine Neoplasia syndrome type 2 (MEN 2).
Pancreatitis Alert: Discontinue Saxenda immediately and seek medical attention if the patient experiences persistent, severe abdominal pain that spreads to the back.
Gallbladder Monitoring: Monitor patients for symptoms of gallbladder problems, such as gallstones or gallbladder inflammation, during significant weight loss.
Avoid Counterfeits: Purchase Saxenda only from licensed physical pharmacies to ensure the product has been stored correctly and is authentic.

Historical Context

Saxenda was developed by Novo Nordisk as a higher-dose formulation of liraglutide specifically designed for chronic weight management. The clinical development was evaluated under the SCALE phase 3 clinical trial program, which showed that once-daily subcutaneous injections of 3.0 mg liraglutide led to significant reductions in body weight compared to placebo. Based on these findings, the US FDA approved Saxenda in December 2014, and the European Medicines Agency followed in 2015.

In the Philippines, Saxenda was approved by the FDA and introduced to the medical community, providing a daily injection option for obesity management. Over the years, the drug has established a strong clinical record, supported by international studies showing its efficacy in diverse populations. It remains a widely prescribed daily GLP-1 therapy across the country for chronic weight management.

Challenges and Controversies

Cost and Accessibility Barriers

The high cost of Saxenda is a major barrier to access in the Philippines. Since the medication is paid for out-of-pocket, its benefits are largely limited to patients with higher incomes. This creates health equity challenges, as many lower-income patients who could benefit from its cardiovascular and metabolic protective properties cannot afford the monthly cost of therapy.

Off-Label Use and Supply Management

The popularity of Saxenda on social media has driven demand for cosmetic weight loss among individuals who do not meet clinical criteria. This demand has contributed to supply shortages, affecting availability for patients with clinical obesity who require the medication for their health. Medical societies continue to advise prioritizing patients with established medical needs.